In this study, we found that BIM intron 2 deletion polymorphism was not associated with TKI resistance in CML patients (OR = 1.24, 95% CI 0.79–1.95). The gene discussed is BCL2L11; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.